title: Increased levels of interleukin-6 (IL-6) in serum and spontaneous in vitro production of IL-6 by lymph node mononuclear cells of patients with angio-immunoblastic lymphadenopathy with dysproteinemia (AILD), and clinical effectiveness of cyclosporin A.
abstract: Serum levels of cytokines and in vitro cytokine production by lymph node mononuclear cells (LNMC) were studied in four patients with angio-immunoblastic lymphadenopathy with dysproteinemia (AILD) or AILD-type T cell lymphoma. An increased level of serum interleukin-6 (IL-6) was detected on initial diagnosis in both of two patients examined. Spontaneous production of IL-6 by LNMC was detected in all four patients studied. Immunosuppressive therapy with cyclosporin A (CsA) was attempted in a 68-year-old man, who was refractory to intensive combination chemotherapy. The increased level of IL-6 in this patient decreased to normal within 3 weeks of CsA administration and the patient became symptom-free. One and a half months later, the IL-6 level gradually increased along with clinical exacerbation. We also measured serum levels of IL-1 alpha, IL-2, IL-4, IFN-alpha, gamma and TNF-alpha in parallel with IL-6, but these factors were only sporadically detected. IL-6 production by LNMC was stimulated by IL-2 but inhibited by CsA. These observations suggest that IL-6 is one of the important cytokines to be involved in the pathophysiology of AILD and CsA is a useful reagent for relieving symptoms.
authors: Department of Hematology, Nagasaki University School of Medicine, Japan.
authors: M
authors: M
authors: Yamamura
authors: M
authors: M
authors: Honda
authors: Y
authors: Y
authors: Yamada
authors: T
authors: T
authors: Itoyama
authors: H
authors: H
authors: Sohda
authors: T
authors: T
authors: Yubashi
authors: S
authors: S
authors: Momita
authors: S
authors: S
authors: Kamihira
authors: Y
authors: Y
authors: Ohmoto
authors: M
authors: M
authors: Tomonaga
mesh_terms: D000368:Aged; D001796:Blood Protein Disorders / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism; D016572:Cyclosporine / Q000627:therapeutic use*; D006801:Humans; D007119:Immunoblastic Lymphadenopathy / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D015850:Interleukin-6 / Q000096:biosynthesis* / Q000097:blood* / Q000502:physiology; D007963:Leukocytes, Mononuclear / Q000378:metabolism*; D008198:Lymph Nodes / Q000166:cytology* / Q000378:metabolism; D016399:Lymphoma, T-Cell / Q000097:blood / Q000188:drug therapy / Q000378:metabolism; D008297:Male; D008875:Middle Aged
chemical_list: D007166:Immunosuppressive Agents; D015850:Interleukin-6; D016572:Cyclosporine